(CA)n Dinucleotide repeat polymorphism at the 5'-end of the aldose reductase gene is not associated with microangiopathy in Caucasians with long-term diabetes mellitus 1

Berend Isermann1,2, Susanne Schmidt1, Angelika Bierhaus3, Stephan Schiekofer3, Valentin Borcea1, Reinhard Ziegler1, Peter P. Nawroth3 and Eberhard Ritz1

1 Department of Medicine University of Heidelberg, Heidelberg, Germany 2 Current address: Blood Research Institute, Milwaukee, USA 3 Section Vascular Medicine, Department of Medicine IV, University Tübingen, Germany

Sir,

Initial evaluations of a CA dinucleotide repeat polymorphic marker of the ALR2-gene suggested that the CA23 (Z-2) allele confers an increased risk of microvascular diabetic complications, whereas the CA25 (Z+2) allele was a marker of protection [1–3]. However, recent studies in type 1 [4] and in type 2 diabetic patients [5,6] did not find an association of the ALR2 polymorphism with diabetic nephropathy. We compared the frequency of the ALR2 polymorphism with microvascular and macrovascular complications in a large population of German type 1 diabetic patients.

In a blinded cross-sectional study the ALR2 polymorphism was initially analysed in 274 German type 1 diabetic patients born in South Germany. Patients with a duration of diabetes <10 years (patients with diabetic complications) and <20 years (patients without diabetic complications), respectively, were excluded. Thus, of the 274 patients initially approached 174 and 122 patients were evaluated for microvascular and macrovascular complications, respectively. Patients were considered to have diabetic nephropathy if albumin concentration was higher than 20 mg/l in the morning urine sample on at least two out of three consecutive occasions over 12 months. Diabetic nephropathy was always associated with diabetic retinopathy. The diagnosis of non-proliferative or proliferative diabetic retinopathy was established using fundoscopy by an ophthalmologist after dilatation of the pupils. Coronary heart disease (CHD) was diagnosed when cardiovascular disease was found by stress ECG, or when there was a history of documented myocardial infarction or of persistent angina pectoris, respectively. PCR was performed as described by Ko et al. [1]. Aliquots (4 µl) of amplified DNA were electrophoresed on a 5% formamide–urea gel together with cloned and sequenced reference PCR-products (PCRR2.1 vector, Invitrogen, Carlsbad, CA, USA). Frequency differences of ALR2 alleles between groups were tested using 2x2 contingency tables and the {chi}2 test or the two-tailed Fisher's exact test.

All nine alleles found by electrophoresis were confirmed by sequencing. When comparing patients with either retinopathy only or with nephropathy to patients without these microvascular complications no significant differences in the frequency of the ALR 2 alleles (Table 1Go) were observed. Patients with CHD were older (55.3 years vs 47.4 years), but did otherwise, especially in respect to disease duration and incidence of nephropathy, not differ from patient without CHD. The Z+2 allele was not found in any patient with the diagnosis of CHD (14.1% in patients without CHD, Table 1Go). However, following Bonferroni correction for multiple testing this difference was not significant.


View this table:
[in this window]
[in a new window]
 
Table 1. Frequency (percentage) of 5'-ALR2 microsatellite alleles in type 1 diabetic patients without diabetic complications after 20 years of diabetes mellitus, or with diabetic complications after 10 years of diabetes mellitus

 
An association between the ALR polymorphism and nephropathy has been only reported in type 1 diabetic patients [2,3], while no association was found in type 2 diabetic patients [5,6]. However, our results are in line with a recent large study in Caucasian type 1 patient [4], which did not find an association of the ALR polymorphism and diabetic nephropathy, and questioned that this locus has a significant role in the pathogenic aetiology of diabetic nephropathy. Conversely, the association of the ALR polymorphism with diabetic retinopathy has been more consistent, and has been found either in patients with early onset [1] or early stages [7,8] of diabetic retinopathy.

Here we report that after an average diabetes duration of 24.1 years (SD 9.8 years) no difference in the frequency of the ALR polymorphism in patients with and without diabetic retinopathy is seen. Background diabetic retinopathy is found in almost all patients after 15 years of diabetes, and proliferative retinopathy increases at a rate of 3% per year after an initial lag period [9]. Therefore, differences in the ALR activity might be important only during the early stages of diabetic retinopathy, whereas at later stages other factors might be more important for the disease progression.

In the present study the Z+2 allele was not found in patients with CHD. This would be compatible with a protective role of this allele, but confirmation in a larger cohort is required. Contribution of the polyol pathway to diabetic macroangiopathy and diabetic heart disease has been suggested [10], but evidence for a genetic basis has been lacking so far. Interestingly, the gene coding for the constitutively expressed endothelial NO synthase has been localised to the same chromosomal region (7q35-7q36) as ALR2 [11].

In conclusion, we did not find an association between the ALR2 polymorphism and diabetic retino- or nephropathy in type 1 diabetic patients. A tentative association between the ALR polymorphism and CHD was found in type 1 diabetic patients, requiring confirmation in an independent patient cohort.

Acknowledgments

This work was in part supported by grants from the Deutsche Forschungsgemeinschaft (BI and PPN). PPN performed this work during the tenure of a Schilling-professorship.

References

  1. Ko CB, Lam KSL, Nelson MSW, Chung SSM. An (AC)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes1995; 44: 727–732[Abstract]
  2. Heesom AE, Hibberd ML, Millward A, Demaine AG. Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes1997; 46: 287–291[Abstract]
  3. Shah VO, Scavini M, Nikolic J et al. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J Clin Endocrinol Metab1998; 83: 2886–2891[Abstract/Free Full Text]
  4. Dyer PH, Chowdhury TA, Dronsfield MJ, Dunger D, Barnett AH, Bain SC. The 5'-end polymorphism of the aldose reductase gene is not associated with diabetic nephropathy in Caucasian type I diabetic patients. Diabetologia1999; 42: 1030–1031[ISI][Medline]
  5. Moczulski DK, Burak W, Doria A et al. The role of aldose reductase gene in the susceptibility to diabetic nephropathy in type II (non-insulin-dependent) diabetes mellitus. Diabetologia1999; 42: 94–97[ISI][Medline]
  6. Maeda S, Haneda M, Yasuda H et al. Diabetic nephropathy is not associated with the dinucleotide repeat polymorphism upstream of the aldose reductase (ALR2) gene but with erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes. Diabetes1999; 48: 420–422[Free Full Text]
  7. Kao YL, Donaghue K, Chan A, Knight J, Silink M. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes. Diabetes1999; 48: 1338–1340[Free Full Text]
  8. Ichikawa F, Yamada K, Ishiyama-Shigemoto S, Yuan X, Nonaka K. Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5'-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with type 2 diabetes mellitus. Diabet Med1999; 16: 744–748[ISI][Medline]
  9. Klein R, Klein BEK, Moss SE. The Wisconsin epidomiological study of diabetic retinopathy: a review. Diabetes Metabolism Rev1989; 7: 559–570
  10. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes1997; 46: 292–300[Abstract]
  11. Marsden PA, Heng HH, Duff CL, Shi XM, Tsui LC, Hall AV. Localization of the human gene for inducible nitric oxide synthase (NOS2) to chromosome 17q11.2-q12. Genomics1994; 19: 183–185[ISI][Medline]